The July 25-29 AACC (American Association of Clinical Chemistry) Meeting in Anaheim will have close to 20,000 clinical lab professionals and over 500 exhibitors . A stock rally in the sector was ignited last week by earnings announcements from four major mid-cap players and new product and technology news should help support the rally.As of mid am trading on Monday JY 26 many diagnostic stocks are up 2% with the S&P up 0.9%.
Here is a financial summary from last week’s earnings announcements:
|Company||Symbol||P $||Q2 Rev $||Q2 EPS||PEG||P/S||Sh.Equity $|
One year stock performance of selected Dx cos.vs NASDAQ (QQQQ).
Among the topics that will be covered in Plenary Sessions are: Biomarkers for Alzheimer Disease, the Changing Healthcare Landscape, Stem Cells, Inflammation and Cardiovascular Disease and Systems Medicine (P4).There are several symposia such as Personalized Medicine and Immunosuppression in Solid Organ Transplantation. Laboratory medicine topics are very broad including diabetes, endocrinogy testing, pharmacogenomics,lipid management and sepsis diagnosis.
Here is news on the consolidation in the biomarker and diagnostics area:
Our focus for the Meeting will be companies in the Rayno “Tools and Diagnostics” Portfolio as well as hot topics in laboratory medicine. Some players exhibiting in our universe in addition to those four above are: Abaxis (ABAX), Alera (ALA), GenProbe (GPRO), Luminex (LMNX), Quidel (QDEL), SeraCare (SRLS) and ThermoFisher (TMO) .